The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

CelLBxHealth plc

 ("CelLBxHealth" or "the Company")

Q1 trading update and outlook for 2026

Guildford, UK and Plymouth Meeting, U.S. - 11 May 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology, provides a trading update for Q1 2026 and outlook for FY 2026 (year ending 31 December 2026).

Trading in first quarter of the year, reflected the Company's initial focus on the necessary organisational restructuring required under the revised business strategy. Management have concentrated efforts on securing significant cost-saving measures, whilst ensuring the business is right-sized to deliver on sensible commercial milestones and to execute on key leads within the sales pipeline. Following last year's 60% reduction in headcount the business has been further reduced from 44 full-time employees (FTEs) to 39 FTEs in the first quarter. These actions, combined with additional forecast cost saving efforts, have resulted in reducing annual cash operating costs in 2026 by more than £6.6 million. Further identified costs to be rationalised in Q2 2026 are expected to deliver savings of an additional £0.1 million. Cash at 31 March 2026 was £4.3 million, in-line with expectations and reflecting one-off costs associated with the restructuring of the business.

Outlook for 2026

Whilst making the much-needed cost reductions, as detailed above, there is also an acute focus on driving commercial progress and revenue growth; accordingly the Company has appointed a new head of sales in the US. The Board remains confident in delivering significant growth in 2026 and the qualified sales pipeline continues to build. It remains early in the Company's turnaround, but based on contracted revenues and sales opportunities expected to convert shortly, the Board is confident in delivering revenues for FY 2026 of at least £2.1 million, a 50% increase on FY 2025. There are a number of other opportunities in the sales pipeline that could convert during the remainder of the financial year, which would allow the Company to increase revenue guidance for the full year.

The Company is in advanced discussions with one of the largest private US healthcare providers to use CelLBxHealth's Parsortix® platform in two clinical studies and is also in the final stages of concluding a Master Services Agreement with a top ten global pharmaceutical company for the use of the Parsortix® platform to potentially support drug discovery and development. Further updates will be provided to shareholders in due course. The Company has also completed a sub-lease agreement for a part of its US facility.

The Board remain confident of delivering significant growth in 2026 and beyond and will provide a further update alongside its final results for FY 2025 which will be announced in the latter part of June.

The Company has also recently update its corporate website, which can be viewed here: https://cellbxhealth.com/

For further information:

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® Platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

Commercial focus span three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development.

For more information, visit https://cellbxhealth.com/.